Marea Therapeutics Doses First Patient in Phase 2 Trial of MAR002 for Acromegaly
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J. — October 5, 2026 Marea Therapeutics, LLC, a subsidiary of Lisata...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J. — October 5, 2026 Marea Therapeutics, LLC, a subsidiary of Lisata...
